arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

CANNAPHARMARX, INC.

CPMD
— Price unavailable
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
16 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
44
Health
Weak
Neutral
auto_awesome

Analytical Summary

CANNAPHARMARX, INC. demonstrates solid fundamentals with strength in Return on Common Equity (%). Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap —
Dividend Yield —
Revenue Growth —
Op. Margin -245.8%
ROIC 8.8% ↘
FCF / Share None
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close.

16-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.36M
— —
Net Income Profit after all expenses
$-11.13M
↓ -401.8% —
FCF / Share Free cash flow per share
$-0.01
↑ +78.8% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability
2
Returns ↓
95
Financial Health ↑
43
Cash Quality ↑
25

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 16 years · 63 quarters